Home / General

General

Italy-USA: Los Angeles Will Host the ‘Italy 5K Run’ on June 2

A 5-kilometer run open to everyone to celebrate Italy’s Republic Day

Silvia Chiave, Italian Ambassador in Beverly Hills with the Italian Chamber of Commerce and Beverly Hills Chamber of Commerce.


Silvia Chiave, Italian Ambassador in Beverly Hills with the Italian Chamber of Commerce and Beverly Hills Chamber of Commerce.

LOS ANGELES, May 25, 2022 (GLOBE NEWSWIRE) — The idea behind it is that of an Italian-style ‘street party’: a 5-kilometre mini-marathon open to all, “to gather around June 2 and our flag all the communities in the area.” In an interview with LaPresse, Silvia Chiave, Consul General of Italy in Los Angeles – a city home to some historic Italian communities as well as to the new ‘immigrants’, made up of researchers, students and high-tech entrepreneurs – explained the meaning of the ‘5K Run’ that will take place on June 5 along the streets of Los Angeles Harbor, in front of the Pacific Ocean, to celebrate Italian Republic Day. The idea, the Consul explained, stems from an initiative that has been taking place in New York since 2018: “Then, there was the pandemic, but last year I thought we could finally organise activities in presence.” In addition to the ‘Run’, which will start at 8am on June 5 from San Pedro, there will be a “street party, with animation, music, games for children and families, food, coffee, ice cream… it will be fun,” the Consul assured.

The main sponsor of the initiative, Chiave further explained, is Enel X Way, i.e. Enel’s new division active in the fields of sustainability and electric mobility, which was set up a few weeks ago. “Enel is one of the flagships of Italian companies,” the Consul pointed out, “It has a global reach and a strong presence in this market.” The guest of honour at the event will be Joe Buscaino, the only Italian-American member of the Los Angeles City Council and former candidate for mayor of the city; other well-known personalities will attend, including Alessandro Del Piero. Participants in the June 5 ‘Run’ will receive a variety of gifts and prizes, including two round-trip Rome-Los Angeles airline tickets offered by ITA, which opens the route to the Californian city on June 1, and two nights in two luxury hotels in Tuscany. However, Consul Chiave stressed, “This run is for everyone and families with buggies are also welcome.” The proceeds of the tickets will go to two non-profit organisations: the Little Italy Los Angeles Association and Fondazione Italia, which will allocate them, among other things, to projects for the teaching of the Italian language.

This year’s Republic Day and the ‘5k Run’ organised to celebrate it come at a particularly busy time for the Consulate, Chiave told us: “The number of compatriots continues to increase and we are running at full capacity. Registrations in the AIRE (Register of Italians Residing Abroad) have increased. This place is very attractive, and we try to uphold our services to the level of this very demanding community of Italian-Americans.” In Los Angeles, between world-class universities, capital and companies, the Consul explained, “there is a unique ecosystem for start-ups” in the technology sector.

In short, LA is not only the city of entertainment; the profile of Italians moving here, “very educated young people,” is “very high,” and for this reason, perhaps, they are “more difficult to reach, because the city is huge.”

For more information:
LaPresse SpA Communication and Press Office Director
Barbara Sanicola barbara.sanicola@lapresse.it

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/059fde0b-8650-4b98-ac2c-c21150ff1213

The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.

Philips Foundation publishes its 2021 Annual Report

May 25, 2022

  • Over 17 million people in underserved communities provided with access to quality healthcare in 2021
  • New social impact investment vehicle established to help nurture early-stage social enterprises
  • Disaster relief in times of crisis highlighted by today’s humanitarian assistance to war-torn Ukraine, and projects responding to the COVID-19 pandemic

Amsterdam, the Netherlands Philips Foundation, with its mission to provide access to quality healthcare for underserved communities through meaningful innovation, today  announced the publication of its 2021 Annual Report.

The report highlights 24 projects initiated by Philips Foundation in collaboration with NGOs, government organizations, and community groups in 2021 that helped deliver better access to quality healthcare for more than 17 million people in underserved communities around the world, more than double the number the year before. In total, 28 new initiatives were started, including support for 8 social enterprises and 9 new projects to help hospitals and communities respond to the ongoing COVID-19 pandemic. The report also highlights Philips Foundation’s newly-incorporated social impact investment vehicle, which nurtures early-stage social enterprises.

“Donations alone do not sustainably improve healthcare systems. Maximum impact and long-lasting change can only be achieved through meaningful innovation born of a thorough understanding of local context and needs, cultural behaviors, and standard practices, together with the myriad details associated with the rollout of new solutions or services,” said Margot Cooijmans, Director of Philips Foundation. “Our success in 2021 means we are well on our way to realizing the foundation’s ambition of providing better access to healthcare for 100 million people a year in underserved communities by 2030.”

Philips Foundation focuses on non-communicable diseases (NCDs), mother and child care, and acute (emergency) care, digitalizing and integrating technology-enabled healthcare solutions for underserved communities. The foundation explores ways to empower community health workers by providing them with tools, technologies, and skills that enhance the quality of care they can deliver. Increasing the probability of sustaining healthcare services and make them independent of donations, the foundation supports social entrepreneurs that share its commitment to create positive social impact. Examples of how these approaches are bringing about lasting change include:

  • Deploying technology-enabled solutions Despite its recognized benefits, diagnostic imaging to identify high-risk pregnancies is insufficiently available in many low-resource rural and remote areas, due to a shortage of trained physicians, as well as barriers such as a lack of awareness, distance to hospitals, and high out-of-pocket expenses. For example, Philips Foundation supports multiple projects that leverage the tele-health capabilities of Philips’ handheld point-of-care ultrasound platform to deliver expert remote learning programs for sonographers and midwives, as well as providing real-time support.
  • Empowering community health workers – Completing the ‘last mile’ to connect people living in remote communities with their healthcare system often remains a challenge in limited-resource settings. In collaboration with the ‘Save a Mother’ initiative in Kenya, Philips Foundation is helping to provide community-based healthcare workers with a backpack full of diagnostic devices, from a contactless thermometer to a blood pressure monitor and an automated respiratory rate counter, that helps them diagnose conditions such as pneumonia, early-stage diabetes and high-risk pregnancies.
  • Supporting social entrepreneurs – International NGOs typically fly in two-thirds of the aid supplies they need when responding to a humanitarian crisis because they cannot easily leverage local supply chains. Through its social impact investment vehicle (Philips Foundation Impact Investments B.V.), Philips Foundation is providing financial support and guidance on how to scale up social enterprises such as Solvoz, which created a digital procurement platform that allows aid organizations to quickly identify local sources of the equipment and services needed for rapid disaster response.

Disaster relief in times of crisis
Philips Foundation’s mission is to provide lasting access to healthcare to underserved communities, as well as disaster relief in times of crisis. The foundation helped launch 9 new COVID response projects in 2021, bringing the total number during the pandemic to 50. In response to the humanitarian crisis caused by the war in Ukraine, it is providing ongoing support to get medical equipment, field hospitals, mother and child care products, and medical support to those most in need.

Establishing sustainable healthcare for underserved communities
In September 2021, Philips Foundation incorporated Philips Foundation Impact Investments B.V. – a social impact investment vehicle that aims to accelerate the development of potentially high impact access-to-care opportunities and reduce healthcare inequality by nurturing early-stage social enterprises through investment and support. In 2022, Philips Foundation will also establish the Philips Foundation Knowledge Hub – an open resource database showcasing the projects and the lessons learned as well as scientific articles and findings from Philips Foundation projects with partners around the world.

To read the full Annual Report, click here.

For further information, please contact:

Yannick Eshuijs
Philips Foundation
Tel.: +31 6 1852 6633
E-mail: yannick.eshuijs@philips.com

Ben Zwirs
Philips Group Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

About Philips Foundation
Philips Foundation is a registered non-profit organization established in 2014 – with a mission to provide access to quality healthcare for underserved communities across the globe. By leveraging Philips’ capabilities and combining them with the experience and expertise of non-governmental organizations and other community-focused and impact-driven enterprises, Philips Foundation helps create innovative pathways to open up affordable healthcare for communities most in need. By also partnering with innovative social entrepreneurs rooted in the local ecosystem, Philips Foundation aims to increase access to healthcare for 100 million people a year by 2030. More information on can be found at www.philips-foundation.com

Attachments

Schneider Electric Accelerates Journey to Next Generation Sustainable Industry at Hannover Messe 2022

  • Launches new software, hardware and services innovations to enable industry to accelerate sustainability commitments
  • Reduces electrical energy consumption by 50% in its motor management suite
  • Expands its portfolio of SF6-free green and digital MV switchgear with GM AirSeT™
  • Continues to advance customer business resilience and extends preventive condition-based maintenance service plan to variable speed drives

Hannover Messe – May 25, 2022 Schneider Electric, the leader in the digital transformation of energy management and automation, will unveil several innovations at Hannover Messe 2022 with a single aim: accelerate the path to net zero CO2 emissions for customers and partners.

“Industry continues to undergo a massive period of change,” said Barbara Frei, Executive Vice President, Industrial Automation at Schneider Electric. “Our vision, however, remains constant. We want to create an efficient, open and sustainable industrial world able to adapt to changes in demand, supply chains, technology, and regulations. Digital solutions are by far the fastest way to decarbonize and future-proof operations for employees. Our technology, combined with AVEVA insights, enables enterprises to reach the next industrial generation with unseen levels of efficiency, resiliency and sustainability. With every piece of technology, we aim to empower our customers and their workforce to achieve their sustainability targets.”

Innovations of the Future

Schneider Electric is proud to unveil a range of offers and partnerships, enabling the next generation sustainable industrial world:

  • EcoStruxure Automation Expert 22.0 is the next version of the world’s first software-centric industrial automation system, further enhancing its sustainability capabilities and flexibility in consumer-packaged goods, logistics, water and wastewater operations.
  • EcoStruxure Machine Expert Twin is a scalable digital twin software solution designed to manage the entire machine lifecycle. The software enables original equipment manufacturers (OEMs) to create digital models or real machines to improve efficiency and sustainability, reduce commissioning time, time to market as well as increasing quality costs.
  • An upgrade to the motor management solution, delivers a holistic approach to asset management with an advanced digital management approach. It unifies energy and automation management systems, providing performance optimization (50% less motor downtime), improved return on investments and efficiency across an entire plant (50% less electrical energy consumed).
  • EcoStruxure Service Plan now available for variable speed drives. Harnessing the combined power of our EcoStruxure platform with both remote and on-site expertise, the service provides condition-based maintenance that enables dynamic scheduling for the maintenance of variable speed drives. By remotely monitoring the health of the drives, the solution can anticipate issues and propose corrective actions that can be implemented on-line or on-site with our Field Services Team, complemented by asset health reports and annual consulting. This allows customers to get the right maintenance at the right time, meaning, significantly reducing unscheduled and unnecessary downtime, optimizing site operations, and improving safety for operators and equipment.
  • Schneider Electric showcases GM AirSeT™, the latest addition to its growing family of SF6-free medium voltage switchgear. The latest green and digital solution powered by pure air enables industries and utilities to reduce environmental impact and optimize maintenance and operations.
  • Strengthening Partnerships for Sustainability by empowering partners to look towards supporting and growing with Schneider’s partner ecosystem. The new program includes comprehensive education and training, a simplified product portfolio, an open and collaborative support ecosystem and digital knowledge and expertise. Complementing the Partnerships for Sustainability program are new products in its TransferPacT, PowerPacT and TeSys Giga ranges.
  • Stratus, Schneider Electric and Avnet Integrated are bringing the capabilities of the data center to the network edge. The combination of EcoStruxure™ Micro Data Centre with Stratus® ftServer® enables fast deployment of zero-touch Edge Computing data centres ready for the challenges of an industrial setting.
  • The integration of ETAP’s digital twin solutions with EcoStruxure Power Operation. The integration allows power system engineers to make more informed decisions, avoid potential operator mistakes and plan future systems expansion, improving response times and contingency actions.
  • Schneider Electric introduces the new 24V DC Easy UPS. Created for commercial and industrial environments where power disruption risks business output, the new Easy-UPS minimizes downtime and protects equipment resulting in reduced machine maintenance, and improved control over industrial infrastructure.

“We are proud to be demonstrating the latest collaborations between Schneider Electric and AVEVA at Hannover Messe. Visitors will have the opportunity to discover first-hand how our new concept of Advanced Operations Control can empower industrial businesses. Data-led innovation to accelerate industrial digital transformation is how we contribute to a more sustainable future with Schneider Electric.” said Caspar Herzberg, Chief Revenue Officer, AVEVA.

Schneider Electric key Hannover Messe sessions  

Through keynote presentations, innovation sessions, panel discussions, and interviews with Schneider Electric spokespeople, customers, partners including AVEVA, and industry experts, the company will celebrate the agility and adaptation that has occurred over the past year.

Monday, 30 May

[3-4 PM CEST] Press conference
Schneider Electric and AVEVA executives discuss the company’s strategic thinking and Industries of the Future vision.

Tuesday, 31 May

[9:30-10:30 AM CEST] Press breakfast
An opportunity to find out about Schneider Electric and AVEVA’s latest solutions for industrial resilience, agility and sustainability.

30 May – June 2: Innovation Talks

Innovation Talk 1: Our resilient and sustainable future
Speakers: Niels Wessel, Offer Manager, Industrial Automation, DACH
Karim Helal, Global Innovation Ambassador

The need for next-generation smart manufacturing is urgent. Industrial enterprises need more innovation, automation, eco-efficiency, and agility at all levels – not only for the sustainability of the planet but also for the sustainability of the businesses themselves.

Join this Innovation Talk to learn:

  • How to increase your operational sustainability by digitally integrating energy and automation systems
  • Ways to grow responsible profitability with advanced analytics and industrial software
  • When to tap into domain experts for safety, efficiency, and sustainability
  • The cybersecurity topics you need to know about right now
  • How to leverage an ecosystem of trusted partners to reach and surpass your operational goals

Innovation Talk 2: Next generation industrial automation
Speakers: Leif Juergensen, System Marketing, Next Gen Automation Incubator
Marissa Mueller, Global Innovation Ambassador

The way goods and services are procured, produced, delivered, and consumed is increasingly driven by information technology. More work is done remotely. More interactions are digital. And more operations are automated.

Thriving as a modern industrial operation requires a digital way of thinking, where software and data play starring roles.

Join this talk to learn how to make your operation sustainable, agile, and resilient through secure software-centric industrial automation.

Innovation Session 3: Electricity 4.0 – Our Fastest Route to Net Zero
Speakers: Gerold Goeldner, Head of Marketing Sustainability, Europe Operations and Cordelia THIELITZ, VP Strategy, Europe Operations

Liani Toro Caballero, Global Innovation Ambassador

Over 80% of CO2 emissions are energy-related and over 60% of energy is wasted. To tackle climate change, we need to make energy green and smart. The solution is a world that is more electric and more digital. We call it Electricity 4.0.

In this Innovation Talk, you will:

  • Discover how electricity makes energy green, as it is the most efficient energy and the best vector for decarbonization
  • See how digital innovation makes energy smart, making the invisible visible to eliminate waste
  • Learn how the four industrial revolutions have evolved in parallel with electrical revolutions
  • See how we are helping customers build the New Electric World everywhere and accelerating their journey to net zero

Ahead of the Hannover Messe 2022 event, Schneider Electric has been awarded with the Gold 2022 Hermes Creative Award by the Association of Marketing Communication Professionals (AMCP) in the Event Marketing category, for the “Discover Industries of the Future at Hannover Messe 2022” campaign.

Get your free promo code via this link to join us at Hannover Messe 2022 (30 May – 2 June), an event exploring what industry leaders, including Schneider Electric, are doing to drive the Industries of the Future forward.

About Schneider Electric

Schneider’s purpose is to empower all to make the most of our energy and resources, bridging progress and sustainability for all. We call this Life Is On.

Our mission is to be your digital partner for Sustainability and Efficiency.

We drive digital transformation by integrating world-leading process and energy technologies, endpoint to cloud connecting products, controls, software and services, across the entire lifecycle, enabling integrated company management, for homes, buildings, data centers, infrastructure and industries.

We are the most local of global companies. We are advocates of open standards and partnership ecosystems that are passionate about our shared Meaningful Purpose, Inclusive and Empowered values.

www.se.com

       Follow us on:      

Discover the newest perspectives shaping sustainability, electricity 4.0, and next generation automation on Schneider Electric Insights.

Additional resource:

Hashtags:  #IndustriesOfTheFuture #NextGenAutomation #IndustrialAutomation #UniversalAutomation #EcoStruxure

Azerion announces Executive Committee and Management Board change

Amsterdam, 25 May 2022 – Azerion today announced the appointment of Ben Davey as chief financial officer (CFO), effective as of today. After a distinguished career of nearly 3 years as Azerion CFO and member of the Management Board, Maria del Dado Alonso Sanchez has decided to step down from her roles, leaving the group to pursue other opportunities. She will be available to support the transition until 31 August 2022.

The Supervisory Board will nominate Ben as a member of Azerion’s Management Board at an extraordinary general meeting expected to be held later this year.

Azerion’s co-CEO, Atilla Aytekin said: “I am delighted to welcome Ben as our new CFO, as he combines broad finance and capital markets experience with a deep knowledge of Azerion. I am very grateful to Dado for her tremendous contribution to Azerion over the last few years. She has been instrumental in preparing Azerion for our next chapter as a listed company.”

Ben is currently chief strategy officer at Azerion. He has over 29 years of professional experience in Law, investment banking, strategy and corporate venture capital with an extensive track-record in public and private M&A, equity and debt capital market transactions.

Contact
Investor Relations
ir@azerion.com

Media
press@azerion.com

Disclaimer
This communication may contain information that qualifies as inside information within the
meaning of Article 7(1) of the EU Market Abuse Regulation.

This press release may include forward looking statements. All statements other than statements of historical facts may be forward looking statements. Words and expressions such as believes, estimates, plans, projects, anticipates, expects, intends, may, will, should or other similar words or expressions are typically used to identify forward-looking statements. Forward-looking statements

VV116 Versus PAXLOVID Phase III Registrational Trial for Early Treatment of Mild to Moderate COVID-19 in High Risk Patients Reaches Primary Endpoint

–the study reached its primary endpoint(VV116 was statistically superior) and secondary efficacy endpoint

–VV116 has a favorable safety profile and fewer adverse events than PAXLOVID

SHANGHAI, China, May 25, 2022 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the Phase III clinical study (NCT05341609) comparing the efficacy and safety of VV116 (JT001) and nirmatrelvir/ritonavir (“PAXLOVID”) in the treatment of patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 including death, has reached its pre-specified primary endpoint and secondary efficacy endpoint. The study results show that compared to PAXLOVID, VV116 (JT001) provided patients with a shorter median time to sustained clinical recovery, achieving statistical superiority.

VV116 (JT001) is a new oral nucleoside analog anti-SARS-CoV-2 investigational drug jointly developed by Junshi Biosciences and Vigonvita Life Sciences Co., Ltd (“Vigonvita”). In earlier Phase I trials, VV116 (JT001) exhibited good safety, tolerability, and pharmacokinetics in healthy subjects. At present, the double-blind, placebo-controlled, international multiregional center Phase III trial evaluating VV116 for the treatment of mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 including death is underway, and a number of clinical studies for mild, moderate and severe COVID-19 are also in progress.

The NCT05341609 study is a multicenter, single-blind, randomized, controlled Phase III study evaluating the efficacy and safety of VV116 (JT001) in comparison with PAXLOVID in the early treatment of patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 and death. The trial was conducted after communication with regulatory authorities. A total of 822 patients were enrolled and a single-blind design was adopted so as to conceal the distribution of therapeutic drugs to both the investigators (including the endpoint evaluator) and the study sponsor. The primary endpoint was “time to sustained clinical recovery,” and the secondary endpoints included “percentage of participants who had progression of COVID-19 (defined as progression to severe and/or critical COVID-19 and death from any cause) by Day 28,” “time to sustained disappearance of clinical symptoms,” “percentage of participants who turned negative for SARS-CoV-2,” etc.

The results of this Phase III study, evaluating VV116 (JT001) as a treatment for patients with mild to moderate COVID-19 who are at high risk for progression to severe COVID-19 and death, show that the predetermined primary endpoint has been reached. In comparison with patients in the PAXLOVID arm, those in the VV116 (JT001) arm exhibited a shorter time to sustained clinical recovery and achieved statistical superiority, a result that demonstrates VV116’s (JT001) ability to accelerate the alleviation of COVID-19 symptoms.

In terms of the secondary efficacy endpoints, there were no COVID-19 disease progression or death in the VV116 (JT001) arm or PAXLOVID arm. The research team also observed that VV116 (JT001) showed a trend toward superiority to PAXLOVID in the time to sustained disappearance of clinical symptoms and the time to patient testing negative for SARS-CoV-2 for the first time.

As for safety, VV116 (JT001) has a good safety profile and its overall incidence of adverse events (“AE”) is lower than that of PAXLOVID.

Detailed data will be published by Junshi Biosciences in a medical journal at a later date.

About VV116 (JT001)
VV116 is an oral nucleoside analog drug that can inhibit the replication of SARS-CoV-2. During preclinical pharmacodynamic studies, VV116 exerted an antiviral effect on the original strain of the novel corinavirus and its known variants in vitro; in the mice model, a low dose of VV116 reduced the virus titers below the detection limit, significantly lowered the chances of lung injury and displayed a strong antiviral effect. Preclinical pharmacokinetics and other research results also show that VV116 has high oral bioavailability. Following oral administration and absorption, VV116 is rapidly metabolized into parent nucleoside and widely distributed throughout the body.

VV116 was jointly developed by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences; the Wuhan Institute of Virology, Chinese Academy of Sciences; Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences; Central Asian Center of Drug Discovery and Development Chinese Academy of Sciences / China-Uzbekistan Medicine Technical Park (the Joint Laboratory of the Ministry of Science and Technology under the “The Belt and Road Initiative”); Vigonvita Life Sciences Co., Ltd. (“Vigonvita”); and Junshi Biosciences. Junshi Biosciences and Vigonvita are responsible for the clinical development and industrialization of VV116 worldwide. The areas of cooperation is global aside from five Central Asian countries, Russia, North Africa and the Middle East.

Junshi Biosciences and Vigonvita have completed three Phase I studies with healthy Chinese subjects, and research results have been published in Acta Pharmacologica Sinica, a well-known journal in the pharmaceutical field. VV116 is currently in an international, multicenter Phase III trial, and a number of clinical studies for mild, moderate and severe COVID-19 are in progress.

In 2021, VV116 was approved in Uzbekistan for the treatment of patients diagnosed with moderate to severe COVID-19.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. Among the many drug candidates is JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 and the result of the combined efforts of Junshi Biosciences, the Institute of Microbiology of the Chinese Academy of Science and Lilly. JS016 administered with bamlanivimab has been granted Emergency Use Authorizations (“EUA”) in over 15 countries and regions worldwide. Meanwhile, VV116, a new oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, is in global Phase III clinical trials. The JS016 and VV116 programs are a part of the company’s continuous innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has more than 2,800 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-2250 0300

Goby Global
Bob Ai
bai@gobyglobal.com
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

Rensselaer Polytechnic Institute and Icahn School of Medicine at Mount Sinai Announce Joint Center for Engineering and Precision Medicine in New York City

NEW YORK, May 24, 2022 (GLOBE NEWSWIRE) — Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai recently announced the creation of the Center for Engineering and Precision Medicine (CEPM), one of the first centers in the nation to bridge engineering and engineering science with medicine. This undertaking will build on a wealth of shared basic research discoveries, explore unique therapeutic innovations in cancer, Alzheimer’s, infectious diseases; and tissue degeneration; educate a new generation of biomedical leaders; and develop new technologies and processes that enhance patient outcomes in unprecedented ways. CEPM represents an evolution in the successful partnership between Mount Sinai and RPI, one that has secured over $70 million in shared research funding since 2013 with 90 percent of that provided by the National Institutes of Health.

The joint center located at 619 West 54th Street in Manhattan, will drive advances in point-of-care and point-of-use devices and diagnostics; microphysiological platforms for discovery and diagnosis; robotic surgery; biomedical imaging; therapeutics biomanufacturing; and artificial intelligence and machine learning applied to biomedical data. These engineering advances will improve patients’ quality of life by synergizing state-of-the-art expertise in research and education at the nexus of engineering and medicine.

The center was announced with a ceremonial signing at the new site.

RENSSELAER POLYTECHNIC INSTITUTE & THE ICAHN SCHOOL OF MEDICINE ANNOUNCE JOINT CENTER: New center will bridge engineering and engineering science with medicine to tackle diseases such as cancer, Alzheimer’s, myriad of infectious diseases, and tissue degeneration

“This transformative partnership between Rensselaer and Icahn Mount Sinai recognizes that engineering and engineering science is fundamental to the understanding of biomedical phenomena and is essential to the development of the next generation of precision diagnostics and therapeutics, human health and well-being, and to the training of advanced researchers and physicians,” said Shirley Ann Jackson, PhD, President of Rensselaer Polytechnic Institute. “Innovative research is a foundation of Rensselaer, as our students, faculty, and graduates continue to change the world through scientific and technological advances. This center will continue to fuel medical and scientific discoveries with life-changing impacts across the globe.”

“From highly sensitive and accurate bioimaging systems to new drug target discoveries, the major inventions that have shaped modern medicine were born out of close collaboration between engineers and clinicians,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs of the Mount Sinai Health System. “The CEPM presents a bold new paradigm for that collaboration to continue that we believe will result in unprecedented advances in science, medicine, and human health. In addition, the PhD program will enable us to attract and equip a new generation of researchers with the interdisciplinary engineering and clinical skills to pursue more groundbreaking, impactful research.”

The Center for Engineering and Precision Medicine grew out of the historically collaborative work by Rensselaer and Icahn Mount Sinai researchers in the field of precision medicine, a personalized approach to disease treatment and prevention based on individuals’ biological, environmental, and lifestyle differences. The CEPM will develop new technologies that will revolutionize the way patient care is delivered.

“Engineering is the driving force for an increasing number of important medical breakthroughs,” said Jonathan Dordick, PhD, Institute Professor of Chemical and Biological Engineering at Rensselaer and Co-Director of CEPM. “The joint Center for Engineering and Precision Medicine is ideally positioned to integrate engineering research and education with medicine to develop new diagnostics and treatments at the individual level, making a real difference in people’s lives.”

“Ultimately, the outcome of CEPM will be new, transformative research projects and innovative technologies that shift clinical paradigms,” said Priti Balchandani, PhD, Professor of Diagnostic, Molecular and Interventional Radiology, Neuroscience, and Psychiatry at Icahn Mount Sinai and Co-Director of CEPM. “And we believe this collaboration will generate new start-ups and attract commercial partners who transform the technologies we pioneer into therapeutic solutions that improve health care and have life-changing outcomes for our patients and for society as a whole.”

“The life sciences sector is at the center of New York’s economic and public health future, and this project represents an important step forward toward that future,” said New York City Mayor Eric Adams. “I want to thank Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mount Sinai for their steadfast commitment to New York City. I look forward to the many critical innovations they will produce together.”

“Thanks to the innovative and historic partnership of Rensselaer Polytechnic Institute and the Icahn School of Medicine at Mt. Sinai, the new Center for Engineering and Precision Medicine holds tremendous promise for biomedicine. The Center is part of the expanding and important biotech industry which is critical to our economy and the health of all New Yorkers and Americans. I look forward to supporting the Center for Engineering and Precision Medicine as it grows and makes major contributions to society,” said Congressman Jerrold Nadler.

“This Center will revolutionize medical practices for some of our most devastating diseases. At the core of the City’s vision for life sciences is creating opportunity for all New Yorkers, which our Mayor is working so hard to address. We have an opportunity to welcome Rensselaer Polytechnic Institute to New York City, and with world-class partner, Mount Sinai, watch them change research, make discoveries, and ultimately improve patient care, saving lives,” said Deputy Mayor for Economic and Workforce Development Maria Torres-Springer.

“It’s about helping treat people who are sick and improve the lives and care of New Yorkers,” said New York City Economic Development Corporation President and CEO Andrew Kimball. “New York City is proud to have these leading institutions growing innovation around life sciences on the West Side of Manhattan and helping us put the City on a path to strengthening our future talent. Ultimately, NYCEDC’s goal, like this Center, is to spur new research and develop our talent to translate to new companies, jobs, medicines, and advanced technologies. As the Center continues to expand, we’re excited at the prospect of partnership ahead.”

Rensselaer Polytechnic Institute is the first and one of the most renowned technological research universities in the nation. Rensselaer researchers are internationally recognized for their expertise in biotechnology and biomanufacturing; neuromodulation; tissue engineering, biocomputation, robotics, devices and microfabrication; and artificial intelligence, machine learning, and high-performance computing.

Icahn Mount Sinai is the academic arm of the Mount Sinai Health System, which offers premier medical and research training and education, runs clinical trials with data available from nearly 4 million patients, and translates basic and biomedical research into commercial products.

The CEPM will focus on three critical research areas at the interface of engineering and medicine:

  • Neuroengineering, which exploits minimally invasive control and regulation of neural circuitry to target neurodegenerative diseases; brain-computer/network analysis; neuro-diagnostics; and computational neurobiology
  • Immunoengineering, which focuses on developing designer immune cells; microbiome engineering; on-demand anti-infectives; and synthetic vaccines to help our bodies fight cancer and infectious disease
  • Regenerative and reparative medicine, which encompasses on-demand personalized tissue repair and regeneration; organoids (3D tissue culture that mimics simplified organ function); and cellular reprogramming

To foster innovation, CEPM will develop a five-year joint PhD in engineering and precision medicine that will equip a new generation of researchers with the fundamental biological sciences, data analytics, and engineering knowledge and skills to pursue breakthroughs in medical science. The development of master’s degrees and certificate programs will broaden the CEPM’s academic mission and facilitate research that spans all aspects of disease mechanisms, data, and technologies from molecular to human dimensions. These programs include a joint PhD in engineering and precision medicine, a PhD in the School of Engineering or School of Science at Rensselaer with a concentration in engineering and precision medicine, and a PhD with a combined master’s degree or certificate in entrepreneurship.

Other key leaders include Deepak Vashishth, PhD, CEPM Associate Director and Director of the Center for Biotechnology and Interdisciplinary Studies and Professor of Biomedical Engineering at Rensselaer; and CEPM senior advisors Zahi Fayad, PhD, Director of the BioMedical Engineering and Imaging Institute at Icahn Mount Sinai and Scott L. Friedman, MD, Fishberg Professor of Medicine and Dean for Therapeutic Discovery at Icahn Mount Sinai.

“Healthcare is a human right and everyone, no matter what zip code they live in, should have access to world class care.  Today’s announcement that two world class institutions have joined forces to produce the very latest in biotech research and design in New York City will further the city’s growth as a biotech hub and revolutionize the future of medicine, from personalized tissue design to incision-free neurosurgery,” said Council Member Lynn Schulman, Chair of the City Council Health Committee.

“I am delighted to welcome Mt. Sinai’s newest medical center to the 6th Council District, which will further bolster New York City’s position as an international leader in life and health sciences. The partnership between Rensselaer Polytechnic Institute and the Icahn School of Medicine will focus on some of the toughest health challenges facing us and serve as a model for medical research and innovation,” said Council Member Gale A. Brewer (D-06).

A Media Snippet accompanying this announcement is available by clicking on the image or link below

Contact: 
Rensselaer Polytechnic Institute
Deanna Cohen
518-233-4828
cohend8@rpi.edu

All You Need to Know About Vivid Sydney 2022 From the Rocks to Walsh Bay

Stretching from The Rocks underneath the Sydney Harbour Bridge to one of the city’s most dramatic districts, Walsh Bay, this is a place where history and technology come together under lights

Vivid Sydney


Vivid Sydney

SYDNEY, May 25, 2022 (GLOBE NEWSWIRE) — Tucked into the western edge of Circular Quay and running around the headland into Walsh Bay, this waterfront precinct offers a quieter slice of the Vivid Sydney action. It’s home to some of the most unique works of the whole festival, including an animated projection from our youngest-ever artist and an interactive display that lets visitors walk on water.

VIVID LIGHT

Name: Ephemeral Oceanic
Artists: Atelier Sisu: Zara Pasfield (Australia) / Renzo B. Larriviere (Australia/Peru)
Location: Between Pier 1 and Pier 2/3 Walsh Bay
Interactive | Great for families

Walsh Bay is transformed into a giant bubble bath! Step onto a floating boardwalk that weaves between 150 larger-than-life illuminated spheres. Lit from within, the iridescent orbs change colour throughout the night.

Name: Ninget Universe
Artist: Luca French / Spinifex Group (Australia)
Location: ASN Co Building, Hickson Rd, The Rocks
Great for families | Art & Architecture

Vivid Sydney’s youngest-ever artist, 11-year-old Luca French, created this fantastical realm bursting with myriad creatures, inventions, and planets. Projected onto the ASN Clocktower in The Rocks, it transforms the heritage-listed façade with bold, colourful characters. His imaginary beings celebrate all walks of life and are a metaphor for diversity and integration.

Name: Manta Rain
Artists: Atelier Sisu: Renzo B. Larriviere (Australia/Peru) / Paul Peña Castro (Colombia)
Location: Overseas Passenger Terminal
The Natural World | Great for families | Eco-Conscious

This kinetic light-and-sound sculpture draws inspiration from the instantly recognisable shape of the manta ray and the mystical rainstick. The sculpture moves, mimicking the fins and organic movement of sea creatures. The installation reminds us of the irreplaceable beings that live in the depths of our oceans and the importance of environmental conservation.

Name: Earth Deities
Artist: Ramesh Nithiyendran (Australia)
Location: Hickson Road Reserve
Art & Architecture | Soul of the City

Towering over a Sydney Harbour headland, this contemporary sculpture is part idol, part monster, part hero and speaks to Sydney’s multicultural soul and complex histories. A multi-limbed mythical being, it pulses with a synthesis of dramatic light and sound.

Name: Celestial
Artists: Studio John Fish: Kristian Laemmle-Ruff (Australia) / James Hebblethwaite (South Africa) / Chris Conole (Australia)
Location: Between Pier 4/5 and Pier 6/7 Walsh Bay
The Natural World

This highly polished planetary sphere reflects its surroundings and inspires ideas of unity and interconnectedness. Kinetic motors and an abstract soundtrack add to Celestial’s dynamic movement. The overall effect is mesmerising by day and night and is an experience for young and old to enjoy.

Name: Light Sentinels
Artist: Skunk Control: Nick Athanasiou (Australia)
Location: Walsh Bay Waterfront
The Natural World

The illuminated petals of these giant kinetic flowers create a canopy of colour that spills across the landscape and onto passers-by. Weave amongst them and marvel as the petals mechanically unfurl, revealing a vibrant internal ecosystem.

VIVID MUSIC

ACO Presents Mozart and Britten in a Relaxed Performance

Take a more relaxed approach to classical music at this special performance from Artistic Director Richard Tognetti AO and the Australian Chamber Orchestra. With flexible seating arrangement, adjusted sound and lighting, and quiet spaces to chill out, it’s a new way to experience the wonders of Mozart and Britten.

EAT, DRINK & STAY

  • Refuel with contemporary Italian antipasti, pizza, and pasta at Ventuno, set right on the edge of the Walsh Bay wharf. There’s a dedicated Bambini Menu for the kids and plenty of Italian wine and beer for the adults.
  • Splash out with an authentic Japanese meal at Bay Nine Omakase, an exclusive 10-seat restaurant that’s part of the new Campbell’s Store development. Or get a table with a showstopping view at Harbourfront Seafood Restaurant, just next door.
  • As the name suggests, The Theatre Bar at the End of the Wharf sits at the end of Wharf 4/5 in Walsh Bay, next to Sydney Theatre Company. There are great views of the Sydney Harbour Bridge served up alongside share plates and a mostly Australian wine list.
  • For a front-row seat to all the action on Circular Quay, don’t go past the Park Hyatt Sydney. This luxury hotel offers magnificent views of the Sydney Harbour Bridge, Lighting of the Sails on the Sydney Opera House, the buildings around the CBD, and the brightly lit boats and ferries as they crisscross Sydney Harbour.
  • Spend the night on one of the wharves at the Pier One Sydney, a hotel housed in a beautifully repurposed heritage building. Choose one of the rooms with a bathtub that looks right out at the Sydney Harbour Bridge.

For more information on Vivid Sydney and to book tickets, go to www.vividsydney.com. Get social using @vividsydney #vividsydney.

MEDIA CONTACT: 
Wayne Mitcham, Āmio Limited
M: +64 21 499 550
E: wayne@amio.nz

About Vivid Sydney 

Vivid Sydney is an annual celebration of creativity, innovation, and technology, which transforms Sydney for 23 days and nights. Staged for its 12th year in 2022, Vivid Sydney fuses mesmerising art displays and 3D light projections with exhilarating live music performances and deep-dive discussions from some of the world’s brightest minds, as well as the Sydney Opera House Lighting of the Sails. Vivid Sydney is owned, managed, and produced by Destination NSW, the NSW Government’s tourism and major events agency.

Related Images

Image 1: Vivid Sydney

Image Credit: Destination NSW

Image 2: Earth Deities

Artist: Ramesh Nithiyendran (Photo Credit: Destination NSW)

Image 3: Ephemeral Oceanic

Artists: Atelier Sisu: Zara Pasfield & Renzo B. Larriviere (Photo Credit: Destination NSW)

This content was issued through the press release distribution service at Newswire.com.

Attachment